Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has announced its entry into the Hormone Replacement Therapy (HRT) segment in India by acquiring the brands Progynova® and Cyclo-Progynova®. These are established brands in the women's health space, used for managing menopausal symptoms. The acquisition marks a strategic expansion of Dr. Reddy's domestic product portfolio into a new therapeutic area. The company has not disclosed the deal value or financial details of the transaction.
This acquisition strengthens Dr. Reddy's presence in the women's health segment in India and diversifies its domestic branded portfolio, which could support future revenue growth. The market may view this as a positive strategic move, though the absence of deal value limits immediate valuation impact.